使用双 Toll 样受体配体脂质体佐剂开发 COVID-19 疫苗。
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.
作者信息
Abhyankar Mayuresh M, Mann Barbara J, Sturek Jeffrey M, Brovero Savannah, Moreau G Brett, Sengar Anjali, Richardson Crystal M, Agah Sayeh, Pomés Anna, Kasson Peter M, Tomai Mark A, Fox Christopher B, Petri William A
机构信息
Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, 22903, USA.
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, 22903, USA.
出版信息
NPJ Vaccines. 2021 Nov 18;6(1):137. doi: 10.1038/s41541-021-00399-0.
We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.
我们研发了一种含有双重TLR配体脂质体佐剂的新型冠状病毒刺突亚基疫苗制剂。该疫苗可诱导产生强效的全身性中和抗体，并能完全保护小鼠免受致死性攻击。两次免疫接种可预防肺部损伤，并在受到攻击后清除肺部病毒。这种佐剂疫苗还能引发全身性和局部抗刺突IgA，这可能是新冠疫苗的一个重要特性。
Zotero 插件